Mutant CALR peptide vaccine (MPN immunotherapy)

Current understanding

Peptide vaccines targeting the abnormal C-terminal neoepitope of mutant calreticulin are in early clinical testing as a third modality (alongside antibodies and CAR-T) of mutant-CALR-directed immunotherapy in MPN. The approach aims to elicit T-cell responses against the shared frameshift neoantigen produced by exon 9 CALR mutations. Evidence to date is preclinical/early-phase and synthesized primarily in review form.

Evidence log

• 2026-09-28 — Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm: cross-connection with mutant-calr-peptide-vaccine: Likely duplicate pages covering the same mutant-CALR neoantigen vaccine program; consider merging or cross-linking as evidence accumulates. (novelty: 4)
• 2026 (rece — Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications: cross-connection with inca033989-mpn: The tetrameric CALR–MPL complex with exposed mutant C-terminus underpins both antibody-based (INCA033989) and vaccine-based immunotherapy strategies against the CALR neoepitope. (novelty: 3)

Open questions

Related